Cytodyne

CytoDyn is a clinical-stage biotechnology company focused on the development of leronlimab, a humanized monoclonal antibody targeting the CCR5 receptor. Leronlimab is being investigated across multiple therapeutic areas, including infectious diseases, oncology, and autoimmune conditions. The company's lead program is in HIV, where leronlimab serves as a viral-entry inhibitor with a potentially improved safety profile compared to existing treatments. Additionally, CytoDyn is exploring the drug's efficacy in treating metastatic triple-negative breast cancer and nonalcoholic steatohepatitis (NASH). Headquartered in Vancouver, Washington, the company is publicly traded on the OTCQB market.